AEGERION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Aegerion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 17, 2014 -- AEGR - WDRB 41 Louisville News
AEGERION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Aegerion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 17, 2014 -- AEGR
Wednesday, April 16 2014 10:54 PM EDT2014-04-17 02:54:16 GMT
LOUISVILLE, Ky. (WDRB) --The Rangers are the Army's most elite soldiers who are put into some of the most dangerous situations in Afghanistan. In a story you'll only see on WDRB we got a rare look atMore >>
The Army Rangers choose Fort Knox as the location to prepare for the 3rd Battalion's 20th deployment to Afghanistan.More >>
Follow the WDRB Newsroom, Reporters and Anchors.More >>
Tweets from the WDRB Newsroom, Reporters and Anchors.More >>
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Levi & Korsinsky, LLP
NEW YORK, Feb. 25, 2014 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") (Nasdaq: AEGR) securities between March 15, 2012 and January 9, 2014.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (a) the Company marketed its drugs in violation of the Federal Food Drug and Cosmetic Act; (b) as a result of these violations, the Company exposed itself to heightened regulatory scrutiny by the FDA and other governmental bodies; (c) as a result of the aforementioned, Aegerion's statements regarding the Company's business, operations, and prospects were materially false and misleading.
On January 10, 2014, Aegerion received a subpoena from the U.S. Department of Justice requesting documents relating to the marketing and sale of the Company's JUXTAPID capsules. Upon this news, shares of Aegerion fell almost 11% to close at $65.77 per share.
If you suffered a loss in Aegerion you have until March 17, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/aegerion-pharmaceuticals-aegr.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com